OMER News and Press, Omeros Corporation From 03/15/21

Maintaining their buy rating, the analysts at Bank of America have upgraded the price target of Omeros Corporation ([[OMER]] +1.2%) citing expert views on the potential of the company’s experimental monoclonal antibody narsoplimab for transplant-associated thrombotic microangiopathy.No...

Omeros Corp (OMER) Q4 2020 Earnings Conference Call Mar 01, 2020, 04:30 PM ET Company Participants Jennifer Williams - IR Greg Demopulos - Co-Founder, Chairman, CEO & President Michael Jacobsen - CAO, VP, Finance & Treasurer Daniel Kirby - Chief Commercial Officer, VP & Head, Comm...

Omeros (OMER): Q4 GAAP EPS of -$0.60 beats by $0.09.Revenue of $10.63M (-68.2% Y/Y) misses by $4.28M.Press Release For further details see: Omeros EPS beats by $0.09, misses on revenue

– Conference Call Today at 4:30 p.m. ET – Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indicat...

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2020, on Monday, March 1, 2021, after the market closes. Omeros management will host a conference call and webcast that day ...

Omeros' Biologics License Application (BLA) for orphan drug narsoplimab was accepted by FDA and was given priority review with FDA action date of July 17, 2021. This BLA is for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a rare...

Omeros has doubled since my last (10/20) bullish article. The company is still vastly undervalued with its current market cap of ~$1.3 billion. Omeros makes a top tier buyout or collaboration candidate. For further details see: Omeros: On A Tear, More To Come

Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer. In this role, Ms. Dac will be responsible for all commercial operations at Omeros, including overseeing preparations for the commercial launch of narsoplimab, the company&...

Under Priority Review status, the FDA accepts Omeros's (OMER) Biologics License Application ((BLA)) for Narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. The FDA has set target action date of July 17.FDA also indicated in its ...

-- FDA sets PDUFA date of July 17, 2021 -- Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) has been accepte...